 | • レポートコード：MRC2109A039 • 出版社/出版日：Transparency Market Research / 2021年6月8日 • レポート形態：英文、PDF、278ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査レポートは、経口経粘膜治療薬の世界市場について調査し、序論、仮定、調査手法、エグゼクティブサマリー、市場概要、主要インサイト、種類別（錠剤、口腔内フィルム、液体・スプレー、ジェル、その他）分析、浸透経路別分析、流通チャンネル別分析、疾患別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを掲載しております。 ・序論 ・仮定 ・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・経口経粘膜治療薬の世界市場規模：種類別（錠剤、口腔内フィルム、液体・スプレー、ジェル、その他） ・経口経粘膜治療薬の世界市場規模：浸透経路別 ・経口経粘膜治療薬の世界市場規模：流通チャンネル別 ・経口経粘膜治療薬の世界市場規模：疾患別 ・経口経粘膜治療薬の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Oral Transmucosal Drugs Market – Scope of Report
TMR’s report on the global oral transmucosal drugs market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global oral transmucosal drugs market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global oral transmucosal drugs market during the forecast period.
The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global oral transmucosal drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global oral transmucosal drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global oral transmucosal drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global oral transmucosal drugs market.
The report delves into the competitive landscape of the global oral transmucosal drugs market. Key players operating in the global oral transmucosal drugs market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global oral transmucosal drugs market that have been profiled in this report.
Key Questions Answered in Oral Transmucosal Drugs Market Report
What are the major drivers, restraints, and opportunities in the market?
What will be the Y-o-Y growth of the global oral transmucosal drugs market between 2021 and 2031?
What are the revenue share projections of key segments of the global oral transmucosal drugs market during the forecast period?
Will North America continue to be the most profitable market for oral transmucosal drugs?
Which factors are anticipated to restrain the global oral transmucosal drugs market during the forecast period?
Which are the leading companies in the global oral transmucosal drugs market?
Research Methodology
A unique methodology has been utilized by TMR to conduct comprehensive research on the growth of the global oral transmucosal drugs market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary research sources referred to by analysts during the production of the global oral transmucosal drugs market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the oral transmucosal drugs market as primary methods.
These primary research respondents have provided exclusive information during interviews, which serves as a validation from the oral transmucosal drugs market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global oral transmucosal drugs market with accuracy. The study also uses the top-down approach to assess the revenue of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global oral transmucosal drugs more reliably and accurately.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Oral Transmucosal Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oral Transmucosal Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.3. Top 3 players operating in the market space
5.4. Clinical Trials & Pipeline Analysis
5.5. Oral Transmucosal Drugs Market SWOT Analysis
6. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Tablets
6.3.1.1. Sublingual Tablets
6.3.1.2. Buccal Tablets
6.3.1.3. Lozenges & Troches
6.3.1.4. Others
6.3.2. Buccal Films
6.3.3. Liquid & Spray
6.3.3.1. Aqueous Solutions
6.3.3.2. Suspensions
6.3.4. Gels
6.3.5. Others
6.4. Market Attractiveness Analysis, by Type
7. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Route of Penetration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Penetration, 2017–2031
7.3.1. Sublingual Mucosa
7.3.2. Buccal Mucosa
7.3.3. Gingival Tissues
7.3.4. Palatal Tissues
7.4. Market Attractiveness Analysis, by Route of Penetration
8. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Indication
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Indication, 2017–2031
9.3.1. Cardiovascular Disorders
9.3.2. Acute Pain Management
9.3.3. Sedation
9.3.4. Erectile Dysfunction
9.3.5. Diabetes
9.3.6. Others
9.4. Market Attractiveness Analysis, by Indication
10. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. South Korea
10.2.5. Latin America
10.2.6. Middle East & Africa
10.3. Market Attractiveness Analysis, by Country/Region
11. North America Oral Transmucosal Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Tablets
11.2.1.1. Sublingual Tablets
11.2.1.2. Buccal Tablets
11.2.1.3. Lozenges & Troches
11.2.1.4. Others
11.2.2. Buccal Films
11.2.3. Liquid & Spray
11.2.3.1. Aqueous Solutions
11.2.3.2. Suspensions
11.2.4. Gels
11.2.5. Others
11.3. Market Value Forecast, by Route of Penetration, 2017–2031
11.3.1. Sublingual Mucosa
11.3.2. Buccal Mucosa
11.3.3. Gingival Tissues
11.3.4. Palatal Tissues
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Indication, 2017–2031
11.5.1. Cardiovascular Disorders
11.5.2. Acute Pain Management
11.5.3. Sedation
11.5.4. Erectile Dysfunction
11.5.5. Diabetes
11.5.6. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Route of Penetration
11.7.3. By Distribution Channel
11.7.4. By Indication
11.7.5. By Country
12. Europe Oral Transmucosal Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Tablets
12.2.1.1. Sublingual Tablets
12.2.1.2. Buccal Tablets
12.2.1.3. Lozenges & Troches
12.2.1.4. Others
12.2.2. Buccal Films
12.2.3. Liquid & Spray
12.2.3.1. Aqueous Solutions
12.2.3.2. Suspensions
12.2.4. Gels
12.2.5. Others
12.3. Market Value Forecast, by Route of Penetration, 2017–2031
12.3.1. Sublingual Mucosa
12.3.2. Buccal Mucosa
12.3.3. Gingival Tissues
12.3.4. Palatal Tissues
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Indication, 2017–2031
12.5.1. Cardiovascular Disorders
12.5.2. Acute Pain Management
12.5.3. Sedation
12.5.4. Erectile Dysfunction
12.5.5. Diabetes
12.5.6. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Route of Penetration
12.7.3. By Distribution Channel
12.7.4. By Indication
12.7.5. By Country/Sub-region
13. Asia Pacific Oral Transmucosal Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Tablets
13.2.1.1. Sublingual Tablets
13.2.1.2. Buccal Tablets
13.2.1.3. Lozenges & Troches
13.2.1.4. Others
13.2.2. Buccal Films
13.2.3. Liquid & Spray
13.2.3.1. Aqueous Solutions
13.2.3.2. Suspensions
13.2.4. Gels
13.2.5. Others
13.3. Market Value Forecast, by Route of Penetration, 2017–2031
13.3.1. Sublingual Mucosa
13.3.2. Buccal Mucosa
13.3.3. Gingival Tissues
13.3.4. Palatal Tissues
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Indication, 2017–2031
13.5.1. Cardiovascular Disorders
13.5.2. Acute Pain Management
13.5.3. Sedation
13.5.4. Erectile Dysfunction
13.5.5. Diabetes
13.5.6. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. South Korea
13.6.6. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Route of Penetration
13.7.3. By Distribution Channel
13.7.4. By Indication
13.7.5. By Country/Sub-region
14. Latin America Oral Transmucosal Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Tablets
14.2.1.1. Sublingual Tablets
14.2.1.2. Buccal Tablets
14.2.1.3. Lozenges & Troches
14.2.1.4. Others
14.2.2. Buccal Films
14.2.3. Liquid & Spray
14.2.3.1. Aqueous Solutions
14.2.3.2. Suspensions
14.2.4. Gels
14.2.5. Others
14.3. Market Value Forecast, by Route of Penetration, 2017–2031
14.3.1. Sublingual Mucosa
14.3.2. Buccal Mucosa
14.3.3. Gingival Tissues
14.3.4. Palatal Tissues
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Indication, 2017–2031
14.5.1. Cardiovascular Disorders
14.5.2. Acute Pain Management
14.5.3. Sedation
14.5.4. Erectile Dysfunction
14.5.5. Diabetes
14.5.6. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Route of Penetration
14.7.3. By Distribution Channel
14.7.4. By Indication
14.7.5. By Country/Sub-region
15. Middle East & Africa Oral Transmucosal Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017–2031
15.2.1. Tablets
15.2.1.1. Sublingual Tablets
15.2.1.2. Buccal Tablets
15.2.1.3. Lozenges & Troches
15.2.1.4. Others
15.2.2. Buccal Films
15.2.3. Liquid & Spray
15.2.3.1. Aqueous Solutions
15.2.3.2. Suspensions
15.2.4. Gels
15.2.5. Others
15.3. Market Value Forecast, by Route of Penetration, 2017–2031
15.3.1. Sublingual Mucosa
15.3.2. Buccal Mucosa
15.3.3. Gingival Tissues
15.3.4. Palatal Tissues
15.4. Market Value Forecast, by Distribution Channel, 2017–2031
15.4.1. Hospital Pharmacies
15.4.2. Retail Pharmacies
15.4.3. Online Pharmacies
15.5. Market Value Forecast, by Indication, 2017–2031
15.5.1. Cardiovascular Disorders
15.5.2. Acute Pain Management
15.5.3. Sedation
15.5.4. Erectile Dysfunction
15.5.5. Diabetes
15.5.6. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Type
15.7.2. By Route of Penetration
15.7.3. By Distribution Channel
15.7.4. By Indication
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Share Analysis, by Company, 2020
16.2. Company Profiles
16.2.1. LTS Lohmann Therapie-Systeme AG
16.2.1.1. Company Overview
16.2.1.2. Company Financials
16.2.1.3. Growth Strategies
16.2.1.4. SWOT Analysis
16.2.2. Soligenix
16.2.2.1. Company Overview
16.2.2.2. Company Financials16.
16.2.2.3. Growth Strategies
16.2.2.4. SWOT Analysis
16.2.3. ZIM Laboratories Limited
16.2.3.1. Company Overview
16.2.3.2. Company Financials
16.2.3.3. Growth Strategies
16.2.3.4. SWOT Analysis
16.2.4. Access Pharmaceutical, Inc.
16.2.4.1. Company Overview
16.2.4.2. Company Financials
16.2.4.3. Growth Strategies
16.2.4.4. SWOT Analysis
16.2.5. C.L Pharm
16.2.5.1. Company Overview
16.2.5.2. Company Financials
16.2.5.3. Growth Strategies
16.2.5.4. SWOT Analysis
16.2.6. Seoul Pharmaceuticals
16.2.6.1. Company Overview
16.2.6.2. Company Financials
16.2.6.3. Growth Strategies
16.2.6.4. SWOT Analysis
16.2.7. Cure Pharmaceutical
16.2.7.1. Company Overview
16.2.7.2. Company Financials
16.2.7.3. Growth Strategies
16.2.7.4. SWOT Analysis
16.2.8. Aquestive Therapeutics, Inc.
16.2.8.1. Company Overview
16.2.8.2. Company Financials
16.2.8.3. Growth Strategies
16.2.8.4. SWOT Analysis
16.2.9. Solvay S.A.
16.2.9.1. Company Overview
16.2.9.2. Company Financials
16.2.9.3. Growth Strategies
16.2.9.4. SWOT Analysis
16.2.10. NAL Pharma
16.2.10.1. Company Overview
16.2.10.2. Company Financials
16.2.10.3. Growth Strategies
16.2.10.4. SWOT Analysis
16.2.11. IntelGenx Corp.
16.2.11.1. Company Overview
16.2.11.2. Company Financials
16.2.11.3. Growth Strategies
16.2.11.4. SWOT Analysis
16.2.12. Izun Pharmaceuticals
16.2.12.1. Company Overview
16.2.12.2. Company Financials
16.2.12.3. Growth Strategies
16.2.12.4. SWOT Analysis
16.2.13. Eisai Co., Ltd
16.2.13.1. Company Overview
16.2.13.2. Company Financials
16.2.13.3. Growth Strategies
16.2.13.4. SWOT Analysis
16.2.14. AstraZeneca
16.2.14.1. Company Overview
16.2.14.2. Company Financials
16.2.14.3. Growth Strategies
16.2.14.4. SWOT Analysis
16.2.15. Otsuka Pharmaceutical Co., Ltd.
16.2.15.1. Company Overview
16.2.15.2. Company Financials
16.2.15.3. Growth Strategies
16.2.15.4. SWOT Analysis
16.2.16. Pfizer, Inc.
16.2.16.1. Company Overview
16.2.16.2. Company Financials
16.2.16.3. Growth Strategies
16.2.16.4. SWOT Analysis
16.2.17. Teva Pharmaceutical Industries Ltd.
16.2.17.1. Company Overview
16.2.17.2. Company Financials
16.2.17.3. Growth Strategies
16.2.17.4. SWOT Analysis
16.2.18. GlaxoSmithKline plc
16.2.18.1. Company Overview
16.2.18.2. Company Financials
16.2.18.3. Growth Strategies
16.2.18.4. SWOT Analysis
16.2.19. Mylan N.V.
16.2.19.1. Company Overview
16.2.19.2. Company Financials
16.2.19.3. Growth Strategies
16.2.19.4. SWOT Analysis
16.2.20. Bristol-Myers Squibb Company
16.2.20.1. Company Overview
16.2.20.2. Company Financials
16.2.20.3. Growth Strategies
16.2.20.4. SWOT Analysis
Table 01: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 03: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 04: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 05: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 07: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 08: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 10: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 11: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 12: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 13: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 14: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 15: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 17: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 18: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 19: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 20: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 22: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 24: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 25: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 26: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 27: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 28: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 29: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 30: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 31: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 32: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 33: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 34: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 35: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 36: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 37: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 38: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 39: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 40: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 41: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 42: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031